New hope for Post-Stroke depression: 14-Day pill trial launches
NCT ID NCT06759558
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 31 times
Summary
This early-stage study tests a 14-day course of the oral drug zuranolone in 6 stroke survivors with moderate to severe depression. Researchers want to see if the drug is safe, well-tolerated, and can improve mood. Participants take 50 mg daily for two weeks and complete mood questionnaires and blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-STROKE DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke South Neurology Clinic 1L
RECRUITINGDurham, North Carolina, 27710-0400, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.